Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
Brain Abnormalities in Neuromyelitis Optica
Arch Neurol 63:390-396, Pittock,S.J.,et al, 2006
Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Combinations of the Presence or Absence of Cerebral Microbleeds and Advanced White Matter Hyperintensity as Predictors of Subsequent Stroke Types
AJNR 27:830-835, Naka,H.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Multiple Sclerosis - The Plaque and Its Pathogenesis
NEJM 354:942-955, Frohman,E.M.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
The Natural History of Primary Lateral Sclerosis
Neurol 66:647-653, Gordon,P.H.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006
Multiple Sclerosis in Twins From Continental Italy and Sardinia: A Nationwide Study
Ann Neurol 59:27-34, Ristori,G.,et al, 2006
Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Clinically Isolated Syndromes, A New Oligoclonal Band Test Accurately Predicts Conversion to MS
Neurol 66:576-578, Masjuan,J.,et al, 2006
Cerebral Microhemorrhages Predict New Disabling or Fatal Strokes in Patients with Acute Ischemic Stroke or Transient Ischemic Attack
Stroke 37:911-914, Boulanger,J-M.,et al, 2006
Diffusion-Weighted MR Imaging Characteristics of an Acute Strokelike Form of Multiple Sclerosis
AJNR 27:1006-1008, Rosso,C.,et al, 2006
Clinical Spectrum of Mutations in SCN1A Gene: Severe Myoclonic Epilepsy in Infancy and Related Epilepsies
Epilepsy Res 70S:S223-S230, Fujiwara,T., 2006
Epilepsy Syndromes in Infancy
Pediatr Neurol 34:253-263, Korff,C.M. &Nordii,D.R.,Jr., 2006
Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder
Brain 129:3150-3164, Jellema, K., et al, 2006
Intracranial Haemorrhages in French Haemophilia Patients (1991-2001): Clinical Presentation, Management and Prognosis Factors for Death
Haemophilia 11:452-458, Stieltjes,N.,et al, 2005
Central Nervous System Manifestations of Mycoplasma Pneumoniae Infections
J Infection 51:343-354, Tsiodras, S.,et al, 2005
The Ependymal "Dot-Dash" Sign: An MR Imaging Finding of Early Multiple Sclerosis
AJNR 26:2033-2036, Lisanti, C.J.,et al, 2005
Unusual Presentation of Central Nervous System Cryptococcal Infection in an Immunocompetent Patient
AJNR 26:2522-2526, Saigal,G.,et al, 2005
Adrenoleukodystrophy
JAMA 294:3131-3134, Moser,H.W.,et al, 2005
Ischaemic Stroke in Young Adults: Predictors of Outcome and Recurrence
JNNP 76:191-195, Nedeltchev, K., et al, 2005
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Anti-a4 Integrin Therapy for Multiple Sclerosis
Neurol 64:1336-1342, Rice,G.P.A.,et al, 2005
Modafinil for Fatigue in MS
Neurol 64:1139-1143, Stankoff,B.,et al, 2005
Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005
Intractable Hiccup and Nausea With Pariaqueductal Lesions in Neuromyelitis Optica
Neurol 65:1479-1482, Misu,T.,et al, 2005
Status Epilepticus: An Evidence Based Guide
BMJ 331:673-677, Walker,M., 2005
Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005
Recent Use of Oral Contraceptives and the Risk of Multiple Sclerosis
Arch Neurol 62:1362-1365, Alonso,A.,et al, 2005
Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke
Stroke 36:1115-1119, Marini,C.,et al, 2005
Overdiagnosis of Multiple Sclerosis and Magnetic Resonance Imaging Criteria
Ann Neurol 58:781-783, Nielsen,J.M.,et al, 2005
Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the "McDonald Criteria"
Ann Neurol 58:840-846, Polman,C.H.,et al, 2005
Diffusion MRI in Multiple Sclerosis
Neurol 65:1526-1532, Rovaris,M.,et al, 2005
Axonal Injury in Early Multiple Sclerosis is Irreversible and Independent of the Short-Term Disease Evolution
Neurol 65:1626-1630, Rovaris,M.,et al, 2005
Pregnancy, Delivery, and Birth Outcome in Women with Multiple Sclerosis
Neurol 65:1961-1963, Dahl,J.,et al, 2005
MRI T2 Hypointensity of the Dentate Nucleus is Related to Ambulatory Impairment in Multiple Sclerosis
J Neurol Sci 234:17-24, Tjoa,C.W.,et al, 2005
The Frequency of Intractable Seizures After Stopping AEDs in Seizure-Free Children With Epilepsy
Neurol 64:973-975, Camfield,P & Camfield,C., 2005
FDA Public Health advisory-Suspended Marketing of Tysabri (natalizumab)
www.fda.gov/cder/drug/advisory/natalizumab.htm.,(Feb 28), US Food and Drug Admin., 2005
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Temporal Relationship Between Elevation of Epstein-Barr Virus Antibody Titers and Initial Onset of Neurological Symptoms in Multiple Sclerosis
JAMA 293:2496-2500, Levin,L.I.,et al, 2005
Triaging Transient Ischemic Attack and Minor Stroke Patients Using Acute Magnetic Resonance Imaging
Ann Neurol 57:848-854, Coutts,S.B.,et al, 2005
Enhanced Benefit of Increasing Interferon Beta-1a Dose and Frequency in Relapsing Multiple Sclerosis
Arch Neurol 62:785-792, Schwid,S.R.,et al, 2005